文献速递胸部肿瘤放疗

PET-CT引导下省略临床靶区在不可切除III期非小细胞肺癌中的可行性:一项II期临床试验

Feasibility of omitting the clinical target volume under PET-CT guidance in unresectable stage III non-small-cell lung cancer: A phase II clinical trial.
PubMed 文献 · Radiother Oncol · 2023-02-09

这项单中心II期临床试验自2016年7月启动,将90例不可切除III期非小细胞肺癌患者随机分入研究组(PET-CT引导下省略CTV)和对照组(勾画CTV),均接受铂类双药同步放化疗。研究组≥3级放射性呼吸事件或食管炎发生率为11.1%,显著低于对照组的28.9%(P=0.035);两组中位PFS、中位OS及失败模式无显著差异。

要点

  • 研究组≥3级放射性呼吸事件或食管炎发生率为11.1%,显著低于对照组28.9%(P=0.035)。
  • 两组中位PFS分别为9.0个月与10.0个月(P=0.597),中位OS分别为31.0个月与26.0个月(P=0.489)。
  • 两组失败模式无显著差异(P=0.826),省略CTV未影响疗效。

核心结论

  • 在PET-CT引导下省略CTV用于不可切除III期非小细胞肺癌的IMRT,具有较高可行性,可减少严重放射性毒性,且不损害疗效。

研究设计与样本

  • 单中心II期临床试验,2016年7月启动,2016年7月至2019年3月共入组90例不可切除III期非小细胞肺癌患者,随机分入研究组(PET-CT引导下省略CTV)和对照组(勾画CTV),均接受铂类双药同步放化疗。
  • 研究组PGTV剂量为60 Gy,30次,每日2 Gy;对照组PCTV剂量为54 Gy,30次,每日1.8 Gy,PGTV剂量为60 Gy,30次,每日2 Gy。
  • 主要终点为≥3级放射性呼吸事件或食管炎发生率;次要终点包括客观缓解率、局部控制率、无进展生存期、失败模式和总生存期。

主要发现

  • 研究组≥3级放射性呼吸事件或食管炎发生率为11.1%,显著低于对照组的28.9%(P=0.035),主要归因于研究组肺和食管受照体积减少。
  • 研究组与对照组中位PFS分别为9.0个月与10.0个月(P=0.597),中位OS分别为31.0个月与26.0个月(P=0.489)。
  • 两组失败模式无显著差异(P=0.826)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This clinical trial aims at investigate the feasibility of CTV-omitted, positron-emission tomography computed tomography (PET-CT) combined with intensity-modulated radiation therapy (IMRT) for unresectable stage III NSCLC. METHODS AND MATERIALS: This was a single-center, phase II clinical trial initiated in July 2016. Patients with unresectable stage III NSCLC undergoing routine IMRT were randomly enrolled into the study group (CTV-omitted under PET-CT guidance) and the control group (CTV-delineated). Patients received platinum-based dual-drug concurrent chemoradio therapy. In the study group, the PGTV dose was 60 Gy given in 30 daily 2 Gy fractions; in the control group, the PCTV dose was 54 Gy given in 30 daily 1.8 Gy fractions, and the PGTV dose was 60 Gy given in 30 daily 2 Gy fractions. The primary endpoint was the incidence of radiation respiratory events or esophagitis with grade 3 or higher. The secondary endpoints included objective response rate (ORR), locate control rate, progression-free survival (PFS), failure pattern and overall survival (OS). RESULTS: A total of 90 patients were enrolled between July 2016 and March 2019. The incidence of radiation respiratory events or esophagitis with grade 3 or higher was 11.1 % in the study group, significantly lower than the rate of 28.9 % in the control group (P = 0.035), basically due to the reduced irradiated volumes of the lungs and esophagus in the study group. The median PFS was 9.0 months versus 10.0 months (P = 0.597), and the median OS 31.0 months versus 26.0 months (P = 0.489) in the study group and the control group, respectively. The failure pattern was not significantly different between the two groups (P = 0.826). CONCLUSION: Omitting the CTV under PET-CT guidance has high feasibility to reduce severe radiation associated toxicity in IMRT for unresectable stage III NSCLC, without compromising the efficacy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Cui T, Zhang A, Cui J, et al. Feasibility of omitting the clinical target volume under PET-CT guidance in unresectable stage III non-small-cell lung cancer: A phase II clinical trial. Radiother Oncol. 2023. PMID: 36764460. doi:10.1016/j.radonc.2023.109505

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。